Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
Phase 1
- Conditions
- Amphetamine-Related Disorders
- Registration Number
- NCT00089440
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.
- Detailed Description
This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
- Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
- Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.
Exclusion Criteria
- Please contact the site for more information.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse effect measures pharmacokinetic assessment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
UCLA Integrated Substance Abuse Program
🇺🇸Los Angeles, California, United States
New York University, School of Medicine
🇺🇸New York, New York, United States
UCLA Integrated Substance Abuse Program🇺🇸Los Angeles, California, United States